Karyopharm Historical Cash Flow
| KPTI Stock | USD 0.64 0.01 2.31% |
Analysis of Karyopharm Therapeutics cash flow over time is an excellent tool to project Karyopharm Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 1.1 M or Depreciation of 622.5 K as it is a great indicator of Karyopharm Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Karyopharm Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Karyopharm Therapeutics is a good buy for the upcoming year.
Karyopharm |
About Karyopharm Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Karyopharm balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Karyopharm's non-liquid assets can be easily converted into cash.
Karyopharm Therapeutics Cash Flow Chart
Add Fundamental
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Karyopharm Therapeutics financial statement analysis. It represents the amount of money remaining after all of Karyopharm Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Total Cashflows From Investing Activities
The net amount of cash used in or generated from a company's investment activities, such as purchasing or selling assets, during a reporting period.Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Most accounts from Karyopharm Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Karyopharm Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.As of now, Karyopharm Therapeutics' Change To Inventory is increasing as compared to previous years. The Karyopharm Therapeutics' current Change To Account Receivables is estimated to increase to about 21.1 M, while Change In Cash is forecasted to increase to (79.5 M).
| 2023 | 2024 (projected) | Issuance Of Capital Stock | 154.7M | 129.8M | Net Borrowings | 150.2M | 133.5M |
Karyopharm Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Karyopharm Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Karyopharm Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 12.0M | (41.6M) | 108.3M | (60.6M) | (83.7M) | (79.5M) | |
| Stock Based Compensation | 15.3M | 24.4M | 29.8M | 35.4M | 21.7M | 18.8M | |
| Free Cash Flow | (191.0M) | (160.4M) | (112.8M) | (149.7M) | (92.7M) | (97.4M) | |
| Change In Working Capital | (13.3M) | 1.4M | (23.2M) | (20.0M) | 31.4M | 33.0M | |
| Begin Period Cash Flow | 118.7M | 130.7M | 89.1M | 197.4M | 136.9M | 98.8M | |
| Other Cashflows From Financing Activities | 78.1M | 10.3M | 63.7M | 4.0M | 1.1M | 1.1M | |
| Depreciation | 974K | 972K | 789K | 621K | 530K | 622.5K | |
| Capital Expenditures | 2.4M | 206K | 145K | 5.7M | 118K | 0.0 | |
| Total Cash From Operating Activities | (190.8M) | (160.2M) | (107.1M) | (149.6M) | (92.7M) | (97.4M) | |
| Net Income | (199.6M) | (196.3M) | (124.1M) | (165.3M) | (143.1M) | (150.3M) | |
| Total Cash From Financing Activities | 124.3M | 172.1M | 73.6M | 193.7M | 1.1M | 1.1M | |
| End Period Cash Flow | 130.7M | 89.1M | 197.4M | 136.9M | 53.2M | 102.9M | |
| Sale Purchase Of Stock | 4.5M | 10.3M | 3.7M | 4.0M | 3.6M | 3.4M | |
| Total Cashflows From Investing Activities | 78.5M | (53.7M) | 141.8M | (104.3M) | (119.9M) | (113.9M) | |
| Other Non Cash Items | 7.2M | 8.4M | 8.1M | (294K) | (3.3M) | (3.1M) | |
| Cash And Cash Equivalents Changes | 11.9M | (41.8M) | 108.4M | (60.1M) | (54.1M) | (51.4M) | |
| Cash Flows Other Operating | (10.3M) | (6.6M) | (25.5M) | (6.4M) | (7.4M) | (7.8M) | |
| Other Cashflows From Investing Activities | 78.7M | (53.5M) | (5.5M) | (104.3M) | (93.8M) | (89.1M) | |
| Change To Netincome | 15.3M | 24.2M | 37.0M | 35.1M | 40.4M | 22.7M | |
| Change To Liabilities | 5.2M | 15.6M | 13.4M | (8.4M) | (7.5M) | (7.2M) | |
| Investments | 78.7M | (53.5M) | 147.6M | (104.1M) | (84.2M) | (80.0M) | |
| Change To Operating Activities | 7.6M | 9.8M | (9.0M) | (16.0M) | (14.4M) | (13.6M) | |
| Issuance Of Capital Stock | 46.2M | 161.8M | 9.9M | 189.8M | 154.7M | 129.8M |
Currently Active Assets on Macroaxis
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 1.247 | Quarterly Revenue Growth 0.077 | Return On Assets (0.34) | Return On Equity (8.91) |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.